Combining a low dose of a targeted cancer-fighter with an anti-inflammatory drug reduces the risk of recurring colorectal polyps, an early sign of colon cancer, by as much as 95 percent, researchers said on Monday.
Go to the Story »
Discuss
Tell a friend
Bury
Discuss
Tell a friend
Bury
BroadcastHealth enables you to find the best stories about health on the web. Users in the community submit and vote on stories to bring you the best content available. Create and broadcast the stories that are important to you!
Learn More!
Comments